These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 35875370)

  • 21. Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects.
    Sachdeva B; Sachdeva P; Ghosh S; Ahmad F; Sinha JK
    Ibrain; 2023; 9(1):90-101. PubMed ID: 37786516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and Safety of Ketamine for Unipolar Depression: a Systematic Review.
    Memon RI; Naveed S; Faquih AE; Fida A; Abbas N; Chaudhary AMD; Qayyum Z
    Psychiatr Q; 2020 Dec; 91(4):1147-1192. PubMed ID: 32852658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine.
    Wohleb ES; Gerhard D; Thomas A; Duman RS
    Curr Neuropharmacol; 2017; 15(1):11-20. PubMed ID: 26955968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Antidepressant-Like Effects of a Clinically Relevant Dose of Ketamine Are Accompanied by Biphasic Alterations in Working Memory in the Wistar Kyoto Rat Model of Depression.
    McDonnell CW; Dunphy-Doherty F; Rouine J; Bianchi M; Upton N; Sokolowska E; Prenderville JA
    Front Psychiatry; 2020; 11():599588. PubMed ID: 33551869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting glutamate signalling in depression: progress and prospects.
    Murrough JW; Abdallah CG; Mathew SJ
    Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral Ketamine for Depression: A Systematic Review.
    Rosenblat JD; Carvalho AF; Li M; Lee Y; Subramanieapillai M; McIntyre RS
    J Clin Psychiatry; 2019 Apr; 80(3):. PubMed ID: 30995364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression.
    Włodarczyk A; Cubała WJ; Gałuszko-Węgielnik M; Szarmach J
    Ther Adv Psychopharmacol; 2021; 11():20451253211011021. PubMed ID: 34046159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.
    Pham TH; Gardier AM
    Pharmacol Ther; 2019 Jul; 199():58-90. PubMed ID: 30851296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants.
    Browne CA; Lucki I
    Front Pharmacol; 2013 Dec; 4():161. PubMed ID: 24409146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood.
    Duncan WC; Ballard ED; Zarate CA
    Handb Exp Pharmacol; 2019; 253():337-358. PubMed ID: 28939975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction.
    Wilson C; Li S; Hannan AJ; Renoir T
    Neuropharmacology; 2020 May; 168():107998. PubMed ID: 32061666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoregulation and antidepressant effect of ketamine.
    Zhang N; Yao L; Wang P; Liu Z
    Transl Neurosci; 2021 Jan; 12(1):218-236. PubMed ID: 34079622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid treatments for depression: Endocannabinoid system as a therapeutic target.
    Sharafi A; Pakkhesal S; Fakhari A; Khajehnasiri N; Ahmadalipour A
    Neurosci Biobehav Rev; 2022 Jun; 137():104635. PubMed ID: 35351488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A historical review of antidepressant effects of ketamine and its enantiomers.
    Wei Y; Chang L; Hashimoto K
    Pharmacol Biochem Behav; 2020 Mar; 190():172870. PubMed ID: 32035078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
    Drewniany E; Han J; Hancock C; Jones RL; Lim J; Nemat Gorgani N; Sperry JK; Yu HJ; Raffa RB
    J Clin Pharm Ther; 2015 Apr; 40(2):125-30. PubMed ID: 25545040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breaking Sad: Unleashing the Breakthrough Potential of Ketamine's Rapid Antidepressant Effects.
    Feifel D
    Drug Dev Res; 2016 Dec; 77(8):489-494. PubMed ID: 27888525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity.
    Kang MJY; Hawken E; Vazquez GH
    Front Psychiatry; 2022; 13():860882. PubMed ID: 35546951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.